JOHNSON & JOHNSON (JNJ) SEC Filings, Jul-Aug 2026

Johnson & Johnson executive Elizabeth Forminard, EVP and Chief Legal Officer, exercised employee stock options covering 9,344 shares of common stock on August 6, 2026. These options, granted under the company’s Long-Term Incentive Plan, had an exercise price of $131.94 per share and an expiration date of February 11, 2029.

On the same date, she acquired 9,344 shares of common stock through the option exercise and then sold a total of 15,918 shares of common stock in open market or private transactions, including 9,344 shares at $257.755 per share and 6,574 shares at $255.932 per share. After the exercise, the reported balance for this specific stock option award was 0 shares.

A shareholder of Johnson & Johnson (JNJ) filed a notice to sell common stock under Rule 144. The planned sale covers 15,918 shares of common stock with an aggregate market value of $4,090,957.06, to be sold on or after 08/06/2026 on the NYSE.

The shares derive from a stock option exercise of 9,344 shares dated 08/06/2026 and multiple restricted stock vesting events between 07/01/2022 and 02/14/2025, totaling 6,574 shares. The filing lists no securities sold during the past three months.

Johnson & Johnson, as an institutional investment manager, submitted a Form 13F Holdings Report covering its reportable equity positions. The summary shows 15 entries in the information table with an aggregate reported value of $798,650,757, rounded to the nearest dollar.

The report also identifies 1 other included manager, Johnson & Johnson Innovation - JJDC, Inc., indicating that this affiliate’s reportable holdings are consolidated under Johnson & Johnson for this Form 13F reporting period.

Johnson & Johnson submitted a Form 144 notice covering potential sales of its common stock through J.P. Morgan Securities LLC on the NYSE. The disclosure also lists issuer transactions in the past three months related to executive compensation, including 4,625 shares of common stock on 02/15/2026 and 43,855 shares on 02/13/2026.

Johnson & Johnson announced that Jennifer Taubert will retire as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee, effective September 1, 2026, after a career spanning more than 21 years with the company.

Under her leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue. She will be succeeded by Tom Cavanaugh, currently Company Group Chairman, North America, Innovative Medicine, who will become Executive Vice President, Worldwide Chairman, Innovative Medicine and join the Executive Committee as part of a planned leadership transition.

Johnson & Johnson completed the acquisition of Firefly Bio, Inc., a biotechnology company with its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The deal is accounted for as an asset acquisition and will result in an in-process research and development charge of approximately $1 billion in the third quarter of 2026. Firefly is expected to dilute adjusted operational earnings per share and adjusted earnings per share by approximately $0.46 in 2026 and approximately $0.08 in 2027.

The company also entered strategic agreements and a collaboration with Sail Biomedicines, involving total initial payments of $785 million, including a $465 million equity investment, up to $140 million in contingent milestone payments, and an exclusive option to acquire Sail for $2.58 billion. Assuming exercise of the option, these agreements are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.18 in 2026 and approximately $1.28 in 2027. Together, the transactions reduce 2026 adjusted operational EPS guidance by about $0.64 to a range of $10.86–$11.01 (midpoint $10.94) and adjusted EPS to $10.96–$11.11 (midpoint $11.04), and shift adjusted pre-tax operating margin from an expected ~75 bps increase to a ~75 bps decrease versus the prior year, a combined impact of ~150 bps, while maintaining 2026 sales growth guidance.

Johnson & Johnson has agreed in principle to a comprehensive resolution of remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state cases. The proposed framework is conditioned on participation from at least 95% of remaining claimants, covering approximately 76,000 ovarian talc claims. It provides per-claim payments under a total $5.5 billion commitment, with a first payment of no more than $3 billion in 2027 and no additional payments due before 2028.

The company links this proposal to a recent MDL court ruling on “specific causation,” after which plaintiffs withdrew certain experts and the court ordered them to show why remaining claims should not be dismissed. Johnson & Johnson states it has already resolved about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes, and that this agreement, if completed, would efficiently conclude 15 years of talc litigation so it can focus on its Innovative Medicine and MedTech businesses.

Johnson & Johnson reported solid top-line growth for the fiscal second quarter ended June 28, 2026. Sales to customers were $25,310 million, up from $23,743 million, and fiscal six‑month sales were $49,372 million versus $45,636 million, reflecting broad-based increases across Innovative Medicine and MedTech.

Quarterly net earnings were $5,534 million, similar to $5,537 million a year earlier, while six‑month net earnings declined to $10,769 million from $16,536 million, largely against a prior period that included approximately $7.0 billion talc reserve reversal recorded in 2025 and stronger other income. Diluted EPS was $2.27 for the quarter and $4.41 for the six months.

Innovative Medicine generated $16,384 million in second‑quarter sales, led by oncology, neuroscience and strong growth from products such as DARZALEX, CARVYKTI and TREMFYA, while Immunology declined as STELARA faced erosion. MedTech sales were $8,926 million, with growth across cardiovascular, surgery, vision and orthopaedics; the MedTech segment absorbed $0.3 billion in Orthopaedics separation costs in the quarter.

Operating cash flows for the fiscal six months were robust at $11,130 million, supporting $6,358 million in dividends and $4,253 million of share repurchases. Cash and cash equivalents were $20,422 million and total shareholders’ equity was $84,971 million. The present value of the reserve for talc‑related matters was approximately $3.7 billion, about 40% classified as current, with roughly 76,000 U.S. plaintiffs; the company states that while individual periods may be affected, it does not expect these matters, net of accruals, to materially impact its overall financial position.

Strategically, J&J agreed to acquire Firefly Bio, Inc. for $1 billion in cash, expected to close in the fiscal third quarter of 2026, and entered a co‑funding agreement with Royalty Pharma plc for up to $0.5 billion through 2027 to support development of JNJ‑4804, with funding recognized as a reduction of research and development expense as services are performed.

Vanessa Broadhurst, EVP, Global Corp Affairs at Johnson & Johnson, exercised employee stock options for 11,129 and 11,925 shares of Common Stock on July 20, 2026 at exercise prices of $129.5100 and $131.9400 per share, then sold 23,054 shares in transactions described as open market or private at a weighted average price of $251.2660 per share. These options were awarded under the issuer's Long-Term Incentive Plan and become exercisable on the third anniversary of the grant date.